VAL Tag

ValiRx PLC – Half-year Report

London, UK., 26 September 2019: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards...

Read More

ValiRx PLC – Update re VAL301

ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that the Company's clinical team has signed an agreement to work with Aptus Clinical Ltd ("Aptus"), the...

Read More

ValiRx PLC – Final Results

ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, today announces...

Read More

ValiRx PLC – ValiSeek Update

ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, provides the following update on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401....

Read More

VALIRX PLC FINAL RESULTS

ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, today announces...

Read More